A Phase 2 interventional study of PF-05212384 and PF-05212384 in Endometrial Neoplasms, sponsored by Pfizer. Terminated at 51 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Endometrial Neoplasms by Pfizer — 2 open to participants now, 3 under way, 1 of them phase 3. Endometrial Neoplasms · Pfizer.
Among the 13 studies in Endometrial Neoplasms by Pfizer, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →2 of the 13 studies in Endometrial Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 5 · Phase 3 1
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 88 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Endometrial Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
The study was prematurely discontinued due to lack confidence in the Stathmin assay as a patient selection criteria and subsequent lack of confidence in the efficacy signal that was observed. The decision to terminate the study was made on January 23, 2014. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PI3K Basal, IV Compound
Drug: PF-05212384
PI3K Activated, Oral Compound
Drug: PF-05212384
Japanese lead in cohort, IV compound
Drug: PF-05212384
154mg IV weekly
Also known as: PKI-587
154mg IV weekly
Also known as: PKI-587
154mg IV weekly
Also known as: PKI-587
Clinical Benefit Response for PF-04691502
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Time frame: 16 weeks from Cycle 1 Day 1
Percentage of Participants With Clinical Benefit Response for PF-05212384
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The primary analysis is based on the clinical benefit rate which is calculated as proportion of participants with a clinical benefit response relative to total number of response evaluable participants. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions; SD does not qualify for CR, PR or Progression. All target lesions must be assessed. SD can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds. A Clopper-Pearson exact 95% CI for the clinical benefit rate is presented in the below table.
Time frame: 16 weeks from Cycle 1 Day 1
Objective Response for PF-04691502
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions. The outcome data table below presents the number of participants with objective response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Time frame: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)
Percentage of Participants With Objective Response for PF-05212384
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)
Progression Free Survival for PF-04691502
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions. On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Time frame: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)
Progression Free Survival for PF-05212384
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
Time frame: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)
Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384
Progression free survival is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the probability of remaining progression-free at 6 months (based on Kaplan-Meier estimates). Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
Time frame: 6 months
Overall Survival (OS) for PF-05212384
OS is defined as the time from the date of Cycle 1 Day 1 to the date of death.
Time frame: 12 months
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Time frame: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Time frame: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days
Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, PTEN protein levels, and PIK3CA gene amplification were to be assessed. Each slide was imaged by whole slide scanning and patient samples were scored as follows: * Pathologist manual score (0, 1+, 2+, 3+) for overall staining intensity of tumor tissue. * Percentage of positive tumor cells staining at 0, 1+, 2+, and 3+. * H-score value (integer between 0 and 300) for tumor cell staining was calculated. The higher the stathmin staining, the higher the stathmin H-score.
Time frame: Prior to Cycle 1 Day 1
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, Phosphatase And Tensin Homolog (PTEN) protein levels, and PIK3CA gene amplification were to be assessed. Stained tissues were evaluated by a board-certified pathologist who provided a manual pathology score (i.e., 0, 1+, 2+, or 3+) and, if appropriate, comments upon the staining of the specimen. The directionality increases from 0 to 3+ with 0 being no staining for PTEN by IHC and 3+ being high staining intensity for PTEN.
Time frame: Baseline and Cycle1 to Cycle 5 where each cycle consist of 28 days
Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Clearance (CL) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.
Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours
Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Time frame: From baseline (-3 days) until 35 days post last dose
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Time frame: From baseline (-3 days) until 35 days post last dose
Number of Treatment-related TEAEs
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Time frame: From baseline (-3 days) until 35 days post last dose
Summary of Treatment-related TEAEs
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Time frame: From baseline (-3 days) until 35 days post last dose
An open-label, Phase 2, four-arm, non-comparative study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-04691502 (an oral PI3K/mTOR inhibitor) and PF-05212384 (an Intravenous \[IV\] Phosphoinositide 3-Kinase \[PI3K\]/Mammalian Target of Rapamycin \[mTOR\] inhibitor).
| Milestone | PF-04691502 8 mg (PI3K Basal) | PF-04691502 6 mg (PI3K Basal) | PF-04691502 8 mg (PI3K Activated) | PF-04691502 6 mg (PI3K Activated) | PF-05212384 154 mg (PI3K Basal) | PF-05212384 154 mg (PI3K Activated) | Lead-in-cohort (LIC) PF-04691502 (4 mg) | LIC PF-05212384 (89 mg) | LIC PF-05212384 (154 mg) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 1 | 11 | 3 | 20 | 20 | 3 | 3 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 1 | 11 | 3 | 20 | 20 | 3 | 3 | 3 |
| Withdrew: Death | 1 | 0 | 8 | 0 | 7 | 12 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 1 | 1 | 3 | 11 | 7 | 3 | 2 | 2 |
| Withdrew: Subject refused futher follow-up | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
| Participants | PF-04691502 (PI3K Basal) | PF-04691502 (PI3K Activated) |
|---|---|---|
| Participants with "Yes" response | 1 | 0 |
| Participants with "No" response | 3 | 11 |
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The primary analysis is based on the clinical benefit rate which is calculated as proportion of participants with a clinical benefit response relative to total number of response evaluable participants. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions; SD does not qualify for CR, PR or Progression. All target lesions must be assessed. SD can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds. A Clopper-Pearson exact 95% CI for the clinical benefit rate is presented in the below table.
| Percentage of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Percentage of Participants With Clinical Benefit Response for PF-05212384 | 52.6 (28.9 to 75.6) | 26.3 (9.1 to 51.2) | 39.5 (24.0 to 56.6) |
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions. The outcome data table below presents the number of participants with objective response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
| Participants response | PF-04691502 (PI3K Basal) | PF-04691502 (PI3K Activated) |
|---|---|---|
| Participants with "Yes" response | 0 | 0 |
| Participants with "No" response | 4 | 11 |
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions.
| Percentage of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Percentage of Participants With Objective Response for PF-05212384 | 21.1 (6.1 to 45.6) | 15.8 (3.4 to 39.6) | 18.4 (7.7 to 34.3) |
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions. On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
| Time to Event (Days) | PF-04691502 (PI3K Basal) | PF-04691502 (PI3K Activated) |
|---|---|---|
| Participant 1 | 1 | 0 |
| Participant 2 | 108 | 0 |
| Participant 3 | 50 | 0 |
| Participant 4 | 199 | 0 |
| Participant 5 | 0 | 54 |
| Participant 6 | 0 | 55 |
| Participant 7 | 0 | 51 |
| Participant 8 | 0 | 1 |
| Participant 9 | 0 | 54 |
| Participant 10 | 0 | 62 |
| Participant 11 | 0 | 53 |
| Participant 12 | 0 | 105 |
| Participant 13 | 0 | 1 |
| Participant 14 | 0 | 54 |
| Participant 15 | 0 | 54 |
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
| Days | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Progression Free Survival for PF-05212384 | 112.0 (59.0 to 167.0) | 89.0 (56.0 to 172.0) | 108.0 (62.0 to 149.0) |
Progression free survival is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the probability of remaining progression-free at 6 months (based on Kaplan-Meier estimates). Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
| Percentage of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384 | 23.2 (7.3 to 44.1) | 25.0 (7.8 to 47.2) | 24.3 (11.6 to 39.5) |
OS is defined as the time from the date of Cycle 1 Day 1 to the date of death.
No measurements were reported for this outcome.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
| Glucose (mg/dL) | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Baseline | 98.5 ± 12.76 | 101.7 ± 26.56 | 100.1 ± 20.60 |
| Cycle 1 Day 15 (n=18,17,35) | 105.3 ± 18.44 | 117.2 ± 61.04 | 111.1 ± 44.26 |
| Cycle 1 Day 22 (n=2,1,3) | 103.0 ± 16.34 | 120.1 ± 0 | 108.7 ± 15.19 |
| Cycle 2 Day 1 (n=17,14,31) | 103.7 ± 19.31 | 114.0 ± 39.42 | 108.3 ± 29.99 |
| Cycle 2 Day 15 (n=17,8,25) | 104.8 ± 13.94 | 106.4 ± 19.36 | 105.3 ± 15.47 |
| Cycle 3 Day 1 (n=14,10,24) | 100.6 ± 16.29 | 125.9 ± 74.50 | 111.1 ± 49.85 |
| Cycle 4 Day 1 (n=12,7,19) | 96.3 ± 10.40 | 98.9 ± 10.20 | 97.3 ± 10.12 |
| Cycle 5 Day 1 (n=9,4,13) | 103.2 ± 15.17 | 112.2 ± 24.37 | 106.0 ± 17.90 |
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
| Insulin (UIU/mL) | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Baseline | 15.2 ± 12.68 | 14.4 ± 7.03 | 14.8 ± 10.36 |
| Cycle 1 Day 15 (n=16,12,28) | 23.6 ± 14.69 | 35.9 ± 37.05 | 28.9 ± 26.79 |
| Cycle 1 Day 22 (n=2,1,3) | 57.6 ± 51.18 | 29.1 ± 0 | 48.1 ± 39.75 |
| Cycle 2 Day 1 (n=17,10,27) | 30.3 ± 28.92 | 28.9 ± 27.85 | 29.8 ± 27.99 |
| Cycle 2 Day 15 (n=14,6,20) | 28.2 ± 29.56 | 21.9 ± 10.49 | 26.3 ± 25.21 |
| Cycle 3 Day 1 (n=13,9,22) | 20.7 ± 13.65 | 35.1 ± 38.66 | 26.6 ± 26.99 |
| Cycle 4 Day 1 (n=11,6,17) | 17.1 ± 10.04 | 24.8 ± 32.32 | 19.8 ± 20.10 |
| Cycle 5 Day 1 (n=7,4,11) | 17.0 ± 15.56 | 15.7 ± 6.20 | 16.5 ± 12.54 |
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
| HbA1c (mg/dL) | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Baseline (n=15,14,29) | 7.8 ± 8.58 | 7.5 ± 6.15 | 7.7 ± 7.37 |
| Cycle 1 Day 15 (n=4,2,6) | 14.7 ± 19.00 | 7.1 ± 1.34 | 12.2 ± 15.25 |
| Cycle 2 Day 1 (n=15,13,28) | 8.4 ± 9.66 | 6.7 ± 1.16 | 7.6 ± 7.05 |
| Cycle 2 Day 15 (n=3,0,3) | 6.7 ± 0.71 | NA ± NA | 6.7 ± 0.71 |
| Cycle 3 Day 1 (n=10,4,14) | 6.0 ± 0.78 | 7.3 ± 1.70 | 6.4 ± 1.19 |
| Cycle 4 Day 1 (n=12,7,19) | 8.9 ± 10.13 | 6.9 ± 1.05 | 8.2 ± 8.01 |
| Cycle 5 Day 1 (n=8,2,10) | 5.9 ± 0.89 | 31.5 ± 36.06 | 11.0 ± 16.17 |
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
| Cholesterol (mg/dL) | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Baseline (n=11,4,15) | 213 ± 54.48 | 186.5 ± 52.43 | 205.9 ± 53.45 |
| Cycle 1 Day 28 (n=15,7,22) | 214.9 ± 49.15 | 161.6 ± 86.51 | 198.0 ± 66.28 |
| Cycle 2 Day 28 (n=16,6,22) | 229.8 ± 44.31 | 127.9 ± 108.69 | 202.0 ± 79.83 |
| Cycle 3 Day 28 (n=11,4,15) | 230.5 ± 48.63 | 137.6 ± 107.02 | 205.7 ± 77.15 |
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
| Triglycerides (mg/dL) | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Baseline (n=11,4,15) | 104.2 ± 40.95 | 133.4 ± 25.75 | 112.0 ± 38.96 |
| Cycle 1 Day 28 (n=15,7,22) | 136.9 ± 70.03 | 134.5 ± 57.21 | 136.1 ± 64.85 |
| Cycle 2 Day 28 (n=16,6,22) | 133.2 ± 71.40 | 117.1 ± 62.77 | 128.8 ± 68.07 |
| Cycle 3 Day 28 (n=10,4,14) | 119.9 ± 64.22 | 130.4 ± 58.01 | 122.9 ± 60.47 |
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, PTEN protein levels, and PIK3CA gene amplification were to be assessed. Each slide was imaged by whole slide scanning and patient samples were scored as follows: * Pathologist manual score (0, 1+, 2+, 3+) for overall staining intensity of tumor tissue. * Percentage of positive tumor cells staining at 0, 1+, 2+, and 3+. * H-score value (integer between 0 and 300) for tumor cell staining was calculated. The higher the stathmin staining, the higher the stathmin H-score.
| Score | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue | 96.4 ± 33.76 | 201.3 ± 34.87 | 146.2 ± 62.9 |
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, Phosphatase And Tensin Homolog (PTEN) protein levels, and PIK3CA gene amplification were to be assessed. Stained tissues were evaluated by a board-certified pathologist who provided a manual pathology score (i.e., 0, 1+, 2+, or 3+) and, if appropriate, comments upon the staining of the specimen. The directionality increases from 0 to 3+ with 0 being no staining for PTEN by IHC and 3+ being high staining intensity for PTEN.
| Percentage of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| PIK3CA Amplification, Amplified (n=17,15,32) | 5.9 ± 33.76 | 6.7 ± 34.87 | 6.3 ± 62.9 |
| PIK3CA Amplification, Nonamplified (n=17,15,32) | 94.1 | 93.3 | 93.8 |
| KRAS Mutation, Positive (n=21,18,39) | 19.0 | 5.6 | 12.8 |
| KRAS Mutation, Negative (n=21,18,39) | 81.0 | 94.4 | 87.2 |
| KRAS Mutation OBSV, Gly12Asp (n=4,1,5) | 25.0 | 100 | 40.0 |
| KRAS Mutation OBSV, Gly12Cys (n=4,1,5) | 25.0 | 0 | 20.0 |
| KRAS Mutation OBSV, Gly12Val (n=4,1,5) | 50.0 | 0 | 40.0 |
| PTEN Stroma Manual Score, 1+ (n=21,19,40) | 4.8 | 0 | 2.5 |
| PTEN Stroma Manual Score, 2+ (n=21,19,40) | 28.6 | 26.3 | 27.5 |
| PTEN Stroma Manual Score, 3+ (n=21,19,40) | 66.7 | 73.7 | 70.0 |
| PTEN Tumor Manual Score, 0 (n=21,19,40) | 23.8 | 21.1 | 22.5 |
| PTEN Tumor Manual Score, 1+ (n=21,19,40) | 38.1 | 31.6 | 35.0 |
| PTEN Tumor Manual Score, 2+ (n=21,19,40) | 38.1 | 47.4 | 42.5 |
| KRAS SCC, Acceptable (n=21,18,39) | 100 | 100 | 100 |
| Stathmin H/L,Tissue, High (n=21,19,40) | 0 | 100 | 47.5 |
| Stathmin H/L,Tissue, Low (n=21,19,40) | 100 | 0 | 52.5 |
| ng.hr/mL | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points. | 15280 ± 24 | 14870 ± 40 |
| ng.hr/mL | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points. | 15080 ± 24 | 15890 ± 52 |
| ng/mL | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points. | 9078 ± 36 | 7057 ± 84 |
| hours | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points. | 35.02 ± 5.32 | 34.09 ± 8.87 |
| hours | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points. | 0.525 (0.500 to 1.07) | 0.650 (0.500 to 1.08) |
| L/hr | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Clearance (CL) of PF-05212384 at Each Specified Time Points. | 10.09 ± 24 | 10.36 ± 40 |
| Litres | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) |
|---|---|---|
| Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points. | 165.6 ± 32 | 174.9 ± 57 |
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
| Number of AEs | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities | 244 | 269 | 513 |
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
| Number of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Participants with AEs | 21 | 18 | 39 |
| Participants with Serious Adverse Events (SAEs) | 3 | 10 | 13 |
| Participants with Grade 3 or Grade 4 AEs | 7 | 14 | 21 |
| Participants with Grade 5 AEs | 1 | 1 | 2 |
| Permanently Discontinued due to AEs | 1 | 5 | 6 |
| Dose Reduced due to AEs | 1 | 5 | 6 |
| Temporary Discontinuations due to AEs | 8 | 10 | 16 |
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
| Number of AEs | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Number of Treatment-related TEAEs | 158 | 161 | 319 |
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
| Number of participants | PF-05212384 (PI3K Basal) | PF-05212384 (PI3K Activated) | PF-05212384 (PI3K Basal + Activated) |
|---|---|---|---|
| Participants with AEs | 21 | 18 | 39 |
| Participants with SAEs | 0 | 3 | 3 |
| Participants with Grade 3 or Grade 4 AEs | 4 | 9 | 13 |
| Participants with Grade 5 AEs | 0 | 0 | 0 |
| Permanently Discontinued due to AEs | 1 | 2 | 3 |
| Dose Reduced due to AEs | 1 | 4 | 5 |
| Temporary Discontinuations due to AEs | 6 | 7 | 13 |
Collected over Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-04691502 8 mg (PI3K Basal) | — | 3/5 (60%) | 5/5 (100%) |
| PF-04691502 6 mg (PI3K Basal) | — | 1/1 (100%) | 1/1 (100%) |
| PF-04691502 8 mg (PI3K Activated) | — | 7/9 (77.8%) | 9/9 (100%) |
| PF-04691502 6 mg (PI3K Activated) | — | 1/3 (33.3%) | 3/3 (100%) |
| PF-05212384 154 mg (PI3K Basal) | — | 3/21 (14.3%) | 21/21 (100%) |
| PF-05212384 154 mg (PI3K Activated) | — | 10/19 (52.6%) | 18/19 (94.7%) |
| Lead-in-cohort (LIC) PF-04691502 (4 mg) | — | 1/3 (33.3%) | 3/3 (100%) |
| LIC PF-05212384 (89 mg) | — | 0/3 (0%) | 3/3 (100%) |
| LIC PF-05212384 (154 mg) | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | PF-04691502 8 mg (PI3K Basal) | PF-04691502 6 mg (PI3K Basal) | PF-04691502 8 mg (PI3K Activated) | PF-04691502 6 mg (PI3K Activated) | PF-05212384 154 mg (PI3K Basal) | PF-05212384 154 mg (PI3K Activated) | Lead-in-cohort (LIC) PF-04691502 (4 mg) | LIC PF-05212384 (89 mg) | LIC PF-05212384 (154 mg) |
|---|---|---|---|---|---|---|---|---|---|
| Oral PainGastrointestinal disorders | 0/5 | 1/1 | 0/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| StomatitisGastrointestinal disorders | 0/5 | 1/1 | 1/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| UrticariaSkin and subcutaneous tissue disorders | 0/5 | 1/1 | 0/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/5 | 0/1 | 2/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| Pneumocystis Jirovecii PneumoniaInfections and infestations | 0/5 | 0/1 | 0/9 | 0/3 | 0/21 | 0/19 | 1/3 | 0/3 | 0/3 |
| Skin InfectionInfections and infestations | 0/5 | 0/1 | 0/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 1/3 |
| Lymphocyte Count DecreasedInvestigations | 0/5 | 0/1 | 0/9 | 0/3 | 0/21 | 0/19 | 1/3 | 0/3 | 0/3 |
| Pneumothorax SpontaneousRespiratory, thoracic and mediastinal disorders | 0/5 | 0/1 | 0/9 | 1/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/1 | 2/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| PneumoniaInfections and infestations | 1/5 | 0/1 | 2/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| Event | PF-04691502 8 mg (PI3K Basal) | PF-04691502 6 mg (PI3K Basal) | PF-04691502 8 mg (PI3K Activated) | PF-04691502 6 mg (PI3K Activated) | PF-05212384 154 mg (PI3K Basal) | PF-05212384 154 mg (PI3K Activated) | Lead-in-cohort (LIC) PF-04691502 (4 mg) | LIC PF-05212384 (89 mg) | LIC PF-05212384 (154 mg) |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/5 | 1/1 | 1/9 | 0/3 | 2/21 | 2/19 | 0/3 | 0/3 | 1/3 |
| Dry MouthGastrointestinal disorders | 1/5 | 1/1 | 2/9 | 2/3 | 3/21 | 4/19 | 0/3 | 0/3 | 0/3 |
| NauseaGastrointestinal disorders | 3/5 | 1/1 | 5/9 | 1/3 | 12/21 | 10/19 | 1/3 | 3/3 | 3/3 |
| StomatitisGastrointestinal disorders | 1/5 | 0/1 | 4/9 | 0/3 | 5/21 | 3/19 | 1/3 | 3/3 | 3/3 |
| Neutrophil Count DecreasedInvestigations | 0/5 | 1/1 | 0/9 | 0/3 | 1/21 | 0/19 | 1/3 | 0/3 | 0/3 |
| Platelet Count DecreasedInvestigations | 1/5 | 1/1 | 1/9 | 0/3 | 0/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| White Blood Cell Count DecreasedInvestigations | 0/5 | 1/1 | 0/9 | 0/3 | 1/21 | 0/19 | 0/3 | 0/3 | 0/3 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/5 | 0/1 | 7/9 | 0/3 | 4/21 | 3/19 | 2/3 | 0/3 | 1/3 |
| HypokalaemiaMetabolism and nutrition disorders | 1/5 | 1/1 | 4/9 | 0/3 | 1/21 | 2/19 | 0/3 | 0/3 | 1/3 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/5 | 0/1 | 0/9 | 0/3 | 2/21 | 3/19 | 0/3 | 0/3 | 3/3 |
| Age, Customized(participants) | PF-04691502 8 mg (PI3K Basal) | PF-04691502 6 mg (PI3K Basal) | PF-04691502 8 mg (PI3K Activated) | PF-04691502 6 mg (PI3K Activated) | PF-05212384 154 mg (PI3K Basal) | PF-05212384 154 mg (PI3K Activated) | Lead-in-cohort (LIC) PF-04691502 (4 mg) | LIC PF-05212384 (89 mg) | LIC PF-05212384 (154 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 - 44 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 45 - 64 years | 2 | 1 | 4 | 3 | 9 | 4 | 2 | 1 | 2 | 28 |
| >= 65 years | 1 | 0 | 7 | 0 | 11 | 16 | 1 | 1 | 1 | 38 |
| Sex: Female, Male(Participants) | PF-04691502 8 mg (PI3K Basal) | PF-04691502 6 mg (PI3K Basal) | PF-04691502 8 mg (PI3K Activated) | PF-04691502 6 mg (PI3K Activated) | PF-05212384 154 mg (PI3K Basal) | PF-05212384 154 mg (PI3K Activated) | Lead-in-cohort (LIC) PF-04691502 (4 mg) | LIC PF-05212384 (89 mg) | LIC PF-05212384 (154 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 11 | 3 | 20 | 20 | 3 | 3 | 3 | 67 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2012 to primary completion in Apr 2014, 27 months.
Results were first posted in May 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gedatolisib